An Overview of Infectious Complications in Children on New Biologic Response-Modifying Agents

• Lee SJ , ChinenJ, KavanaughA: Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins.J. Allergy Clin. Immunol.125(Suppl. 2), S314–S323 (2010).
   PubMed Web of Science ®Google Scholar
• Chan AC , CarterPJ: Therapeutic antibodies for autoimmunity and inflammation.Nat. Rev. Immunol.10, 301–316(2010).
   PubMed Web of Science ®Google Scholar
• Dinarello CA : Anti-inflammatory agents: present and future.Cell140, 935–950(2010).
   PubMed Web of Science ®Google Scholar
• Ilowite NT : Update on biologics in juvenile idiopathic arthritis.Curr. Opin. Rheumatol.20(5), 613–618(2008).
   PubMed Web of Science ®Google Scholar
• Beresford MW , BaildamEM: New advances in the management of juvenile idiopathic arthritis-2: the era of biological.Arch. Dis. Child Educ. Pract. Ed.94, 151–156(2009).
   PubMed Web of Science ®Google Scholar
• Breda L , Del Torto M, De Sanctis S, Chiarelli F: Biologics in Children’s autoimmune disorders: efficacy and safety. Eur. J. Pediatr. doi:10.1007/s00431–010–1238-z. (2010) (Epub ahead of print).
   Web of Science ®Google Scholar
• Singh JA , ChristensenR, WellsGAet al.: Biologics for rheumatoid arthritis: an overview of Cochrane reviews.Cochrane Database Syst. Rev.4, 1–79(2009).
   Google Scholar
• Raychaudhuri SP , NguyenCT, RaychaudhuriSK, GershwinME: Incidence and nature of infectious disease in patients treated with anti-TNF agents.Autoimmun. Rev.9, 67–81(2009).
   PubMed Web of Science ®Google Scholar
• Salvana EM , SalataRA: Infectious complications associated with monoclonal antibodies and related small molecules.Clin. Microbiol. Rev.22, 274–290(2009).
   PubMed Web of Science ®Google Scholar
• Lovell DJ , ReiffA, IlowiteNTet al.; Pediatric Rheumatology Collaborative Study Group: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum.58(5), 1496–1504(2008).
   PubMed Web of Science ®Google Scholar
• Giannini EH , IlowiteNT, LovellDJet al.; Pediatric Rheumatology Collaborative Study Group: Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum.60(9), 2794–2804(2009).
   PubMed Web of Science ®Google Scholar
• Horneff G , SchmelingH, BiedermannTet al.: The German etanercept registry for treatment of juvenile idiopathic arthritis.Ann. Rheum. Dis.63(12), 1638–1644(2004).
   PubMed Web of Science ®Google Scholar
• Horneff G , De Bock F, Foeldvari I et al.; German and Austrian Paediatric Rheumatology Collaborative Study Group: Safety and efficacy of combination of etanercept and methotrexate compared with treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann. Rheum. Dis.68(4), 519–525(2009).
   PubMed Web of Science ®Google Scholar
• Dekker L , ArmbrustW, RademakerCM, PrakkenB, KuisW, WulffraatNM: Safety of anti-TNFα therapy in children with juvenile idiopathic arthritis.Clin. Exp. Rheumatol.22(2), 252–258(2004).
   PubMed Web of Science ®Google Scholar
• Prince FHM , TwiltM, ten Cate R et al.: Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann. Rheum. Dis.68, 635–641(2009).
   PubMed Web of Science ®Google Scholar
• Pain CE , McCannLJ: Challenges in the management of juvenile idiopathic arthritis with etanercept.Biologics3, 127–139(2009).
   PubMedGoogle Scholar
• Burmester GR , MeaseP, DijkmansBAet al.: Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.Ann. Rheum. Dis.68(12), 1863–1869(2009).
   PubMed Web of Science ®Google Scholar
• Ruperto N , LovellDJ, CutticaRet al.; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann. Rheum. Dis.69(4), 718–722(2010).
   PubMed Web of Science ®Google Scholar
• Keane J , GershonS, WiseRPet al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent.N. Engl. J. Med.345(15), 1098–1104(2001).
   PubMed Web of Science ®Google Scholar
• Frank KM , HogarthK, MillerJLet al.: Investigation of the cause of death in a gene-therapy trial.N. Engl. J. Med.361, 161–169(2009).
   PubMed Web of Science ®Google Scholar
• Abinun M , FloodTJ, CantAJet al.: Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000–2007).Mol. Immunol.47(1), 46–51(2009).
   PubMed Web of Science ®Google Scholar
• Eleftheriou D , MeloM, MarksSDet al.: Biologic therapy in primary systemic vasculitis of the young.Rheumatology (Oxford).48(8), 978–986(2009).
   PubMed Web of Science ®Google Scholar
• Maródi L , CasanovaJL: Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?Nat. Rev. Immunol.10(5), 299–300(2010).
   PubMed Web of Science ®Google Scholar
• Puel A , PicardC, LorrotMet al.: Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6.J. Immunol.180(1), 647–654(2008).
   PubMed Web of Science ®Google Scholar
• Yokota S , ImagawaT, MoriMet al.: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial.Lancet371(9617), 998–1006(2008).
   PubMed Web of Science ®Google Scholar
• Cooper N , DaviesEG, ThrasherAJ: Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogglobulinaemia requiring replacement intravenous immunoglobulin.Br. J. Haematol.146(1), 120–122(2009)
   PubMed Web of Science ®Google Scholar
• Terrier B , AmouraZ, RavaudPet al.; Club Rhumatismes et Inflammation: Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AIR registry. Arthritis Rheum. doi:10.1002/art.27541 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Ruperto N , LovellDJ, QuartierPet al.; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group: Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum.62(6), 1792–1802(2010).
   PubMed Web of Science ®Google Scholar
• Notarangelo LD , FischerA, GehaRSet al.; International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies: Primary immunodeficiencies: 2009 update. J. Allergy Clin. Immunol.124, 1161–1178(2009).
   PubMed Web of Science ®Google Scholar
• Casanova J -L, Abel L: Primary immunodeficiencies: a field in its infancy. Science317, 617–619(2007).
   PubMed Web of Science ®Google Scholar
• Casanova J -L, Fieschi C, Zhang S-Y, Abel L: Revisiting human primary immunodeficiencies. J. Intern. Med.264, 115–127(2008).
   PubMed Web of Science ®Google Scholar
• Patel SY , DoffingerR, Barcenas-MoralesG, KumararatneDS: Genetically determined susceptibility to mycobacterial infection.J. Clin. Pathol.61, 1006–1012(2008).
   PubMed Web of Science ®Google Scholar
• Filipe-Santos O , BustamanteJ, ChapgierAet al.: Inborn errors of IL-12/23- and IFN-γ-mediated immunity: molecular, cellular, and clinical features.Sem. Immunol.18, 347–361(2006).
   PubMed Web of Science ®Google Scholar
• Bruns H , MeinkenC, SchauenbergPet al.: Anti-TNF immunotherapy reduces CD8+ T-cell mediated antimicrobial activity against Mycobacterium tuberculosis in humans.J. Clin. Investig.119, 1167–1177(2009).
   PubMed Web of Science ®Google Scholar
• Miller EA , ErnstJD: Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.J. Clin. Investig.119, 1079–1078(2009).
   PubMed Web of Science ®Google Scholar
• Harris J , KeaneJ: How tumour necrosis factor blockers interfere with tuberculosis immunity.Clin. Exp. Immunol.161, 1–9(2010).
   PubMed Web of Science ®Google Scholar
• Medzhitov R : Recognition of microorganisms and activation of the immune response.Nature449(7164), 819–826(2007).
   PubMed Web of Science ®Google Scholar
• Medzhitov R : Inflammation 2010: new adventures of an old flame.Cell140(6), 771–776(2010).
   PubMed Web of Science ®Google Scholar
• Schroder K , TschoppJ: The inflammasomes.Cell140, 821–832(2010).
   PubMed Web of Science ®Google Scholar
• Döffinger R , SmahiA, BessiaCet al.: X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling.Nat. Genet.27(3), 277–285(2001).
   PubMed Web of Science ®Google Scholar
• Picard C , PuelA, BonnetMet al.: Pyogenic bacterial infections in humans with IRAK-4 deficiency.Science.299(5615), 2076–2079(2003).
   PubMed Web of Science ®Google Scholar
• von Bernuth H , PicardC, JinZet al.: Pyogenic bacterial infections in humans with MyD88 deficiency.Science.321(5889), 691–696(2008).
   PubMed Web of Science ®Google Scholar
• von Bernuth H , PuelA, KuCLet al.: Septicemia without sepsis: inherited disorders of nuclear factor-κ B-mediated inflammation.Clin. Infect. Dis.41(Suppl. 7), S436–S439 (2005).
   PubMed Web of Science ®Google Scholar
• Masters SL , SimonA, AksentijevichI, KastnerDL: Horror autoinflammatoricus: The molecular pathophysiology of autoinflammatory disease.Annu. Rev. Immunol.27, 621–668(2009).
   PubMed Web of Science ®Google Scholar
• Kastner DL , AksentijevichI, Goldbach-ManskyR: Autoinflammatory disease reloaded: a clinical perspective.Cell140, 784–790(2010).
   PubMed Web of Science ®Google Scholar
• Henderson C , Gorbach-ManskyR: Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals.Clin. Immunol.135, 210–222(2010).
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R , DaileyN J, Canna SW et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1{β} inhibition. N. Engl. J. Med.355, 581–592(2006).
   PubMed Web of Science ®Google Scholar
• Lachmann HJ , Kone-PautI, Kuemmerle-DeschnerJBet al.: (Canakinumab in CAPS Study Group). Use of canakinumab in the cryopyrin-associated periodic syndrome.N. Engl. J. Med.360(23), 2416–2425(2009).
   PubMed Web of Science ®Google Scholar
• Pascual V , AllantazF, ArceE, PunaroM, BanchereauJ: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.J. Exp. Med.201, 1479–1486(2005).
   PubMed Web of Science ®Google Scholar
• Gattorno M , PicciniA, Lasigli'eDet al.: The pattern of response to anti–interleuk in-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.Arthritis Rheum.58(5), 1505–1515(2008).
   PubMed Web of Science ®Google Scholar
• Ohlsson V , BaildamE, FosterH, JandialS, PainC, StrikeH, RamanAV: Anakinra treatment for systemic onset juvenile idiopathic arthritis (soJIA).Rheumatology47, 555–556(2008).
   PubMed Web of Science ®Google Scholar
• Dinarello CA : Blocking IL-1 in systemic inflammation.J. Exp. Med.201, 1355–1359(2005).
   PubMed Web of Science ®Google Scholar
• Diak P , SiegelJ, La Grenade L, Choi L, Lemery S, McMahon A: Malignancy in children and tumor necrosis factor-α blockers: forty-eight cases reported to the food and drug administration. Arthritis Rheum. doi:10.1002/art.27511 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• McCroskery P , WallaceCA, LovellDJet al.: Summary of worldwide pediatric malignancies reported after exposure to etanercept.Pediatr. Rheumatol. Online J.8(1), 18 (2010).
   PubMedGoogle Scholar
• Smith MY , SobelRE, WallaceCA: Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry.Arthritis Care Res.62, 800–804(2010).
   PubMed Web of Science ®Google Scholar
• Lepore L , PaloniG, CaorsiRet al.: Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra.J. Pediatr. doi:10.1016/j.jpeds.2010.02.040. (2010) (Epub ahead of print).
   Google Scholar
• Solovic I , SesterM, Gomez-ReinoJJet al.: The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement.Eur. Respir. J. doi: 09031936.00028510v1-erj00285–2010 (2010) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention: updated guidelines for using interferon γ release assays to detect Mycobacterium tuberculosis infection; United States, 2010. MMWR59(RR-5), 1–25(2010).
   PubMedGoogle Scholar

Websites

• FDA alert (9/4/2008): The US FDA information for healthcare professionals that histoplasmosis and other invasive fungal infections are not consistently recognized in patients taking TNF blockers, which has resulted in delays in appropriate treatment, sometimes resulting in death www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm
   Google Scholar
• FDA alert (4/8/2009): The US FDA warning, highlighting the increased risk of cancer in children and adolescents who receive TNF blockers www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm
   Google Scholar